Investor's Business Daily on MSN11h
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.
Hosted on MSN1mon
New type of cerebellar ataxia discovered: How the immune system destroys the cerebellum
Cerebellar ataxia is a neurological disorder of the ... a significant loss of substance in the affected cerebellum. After treatment with anti-inflammatory drugs and immunotherapy with the active ...
Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application For The Treatment Of Spinocerebellar Ataxia
Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, Our NDA filing is the culmination of over 8 years of clinical research a ...
Why Biohaven Stock Triumphed on Tuesday
News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain ...
WebMD11y
Vitamins by Condition
Considering taking supplements to treat cerebellar ataxia? Below is a list of common natural remedies used to treat or reduce the symptoms of cerebellar ataxia. Follow the links to read common ...
sciencex3y
New Potential of Memantine for Treatment of Cerebral Ataxia Uncovered
Treatment of mice with cerebellar dysfunction with memantine resulted in not ... memantine could be a promising neuroprotective drug for patients with spinocerebral ataxia. We plan to investigate its ...
Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia
Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological ...
Cerebellar serotonin offers potential new strategy for relieving anxiety
Understanding the neural circuits that drive anxiety may help researchers discover circuit-specific targets and therefore ...
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Morningstar21d
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation
Solid Biosciences received the Food and Drug Administration's fast-track designation for a gene therapy intended to treat a condition known as Friedreich's ataxia. Solid Biosciences will move the ...
The Scientist3mon
Sleep Disruptions and Impaired Muscle Control in Ataxia May Share a Culprit
Previously, the group investigated two models of dystonia, a different motor disorder, and demonstrated that preventing brainstem neurons from communicating with the cerebellum disturbed ... To model ...
Biohaven Ltd.: Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...